Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

September 26, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

July 31, 2029

Conditions
Advanced Non-squamous Non-small-cell Lung CancerAdvanced Squamous Non-Small Cell Lung CarcinomaMetastatic Non-squamous Non Small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung CarcinomaNon-small Cell Lung CancerNon-small Cell Lung Cancer Stage IIINon-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer Recurrent
Interventions
BIOLOGICAL

Olvimulogene nanivacirepvec

Olvi-Vec is an engineered oncolytic vaccinia virus

DRUG

Platinum chemotherapy: carboplatin or cisplatin

Administered according to local practice.

DRUG

Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC

Administered according to local practice.

DRUG

Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab

Administered according to local practice.

DRUG

Docetaxel

Administered according to local practice.

Trial Locations (16)

21201

RECRUITING

University of Maryland Medical Center Greenebaum Comprehensive Cancer Center, Baltimore

32763

RECRUITING

Mid Florida Hematology and Oncology Center, Orange City

33013

RECRUITING

Bioresearch Partner, Hialeah

33065

RECRUITING

Oncology & Hematology Associates of West Broward, Coral Springs

33136

RECRUITING

University of Miami - Sylvester Comprehensive Cancer Center, Miami

33155

RECRUITING

Bioresearch Partner, Miami

33316

RECRUITING

Helios Clinical Research, Fort Lauderdale

33322

RECRUITING

BRCR Medical Center, Inc., Plantation

34711

RECRUITING

Clermont Oncology Center, Clermont

44718

RECRUITING

Gabrail Cancer and Research Center, Canton

48126

RECRUITING

Michigan Hematology and Oncology Consultants, Dearborn

48336

RECRUITING

Oakland Medical Group, Farmington Hills

53081

RECRUITING

Sheboygan Cancer & Blood Center, Sheboygan

77521

RECRUITING

World Research Link, Baytown

78745

RECRUITING

Texas Oncology - Austin Central, Austin

86442

RECRUITING

Pioneer Research Center, LLC, Bullhead City

Sponsors
All Listed Sponsors
collaborator

Newsoara Biopharma Co., Ltd.

INDUSTRY

lead

Genelux Corporation

INDUSTRY

NCT06463665 - Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | Biotech Hunter | Biotech Hunter